At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
In Brief
A Phase 3 clinical trial evaluating Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, and 9 other interventions for Extraocular Retinoblastoma. Completed, enrolled 60 participants across 73 sites in 6 countries.
Detailed Summary
This phase III trial is studying the side effects and how well giving combination chemotherapy together with autologous stem cell transplant and/or radiation therapy works in treating young patients with extraocular retinoblastoma. Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and/or bone marrow and stored. More chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Radiation therapy uses high energy x-rays to kill tumor cells. Giving radiation therapy after combination chemotherapy and/or autologous stem cell transplant may kill any remaining tumor cells.
Study Details
Timeline
Interventions
Undergo peripheral blood stem cell or bone marrow transplant
Undergo peripheral blood stem cell or bone marrow transplant
Given IV
Given IV
Given IV
Given IV
Given SC
Undergo peripheral blood stem cell or bone marrow transplant
Undergo radiotherapy
Given IV
Given IV